BIONIZ THERAPEUTICS
Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approval and commercialization. At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors. It was founded in 2009 and headquartered in Irvine, California.
BIONIZ THERAPEUTICS
Industry:
Biotechnology Health Care Medical Device
Founded:
2009-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.bioniz.com
Total Employee:
11+
Status:
Active
Contact:
(949)273-6000
Email Addresses:
[email protected]
Total Funding:
14.32 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS AWS Global Accelerator
Similar Organizations
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Investors List
Takeda Ventures
Takeda Ventures investment in Series A - Bioniz Therapeutics
Signatures Capital
Signatures Capital investment in Series A - Bioniz Therapeutics
David Pyott
David Pyott investment in Series A - Bioniz Therapeutics
Cota Capital
Cota Capital investment in Series A - Bioniz Therapeutics
Signatures Capital
Signatures Capital investment in Seed Round - Bioniz Therapeutics
Official Site Inspections
http://www.bioniz.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Bioniz Therapeutics"
Bioniz Therapeutics - Crunchbase Company Profile
Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of …See details»
Equillium Acquires Bioniz Therapeutics Significantly Expanding …
Feb 16, 2022 Equillium is also obligated to pay Bioniz stockholders up to $57.5 million in potential development milestone payments across three Bioniz clinical candidates (BNZ-1, …See details»
Bioniz Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Explore Bioniz Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 15 news, and 6 literature, Disease Domain:Immune System Diseases, …See details»
Bioniz Therapeutics Company Profile 2024: Valuation, Investors ...
Almirall, Babak Yazdani, Broadway Angels, Catalina Ventures, and Cota Capital are 5 of 10 investors who have invested in Bioniz Therapeutics. Who are Bioniz Therapeutics’s …See details»
www.bioniz.com
Www.bioniz.comSee details»
Bioniz Therapeutics - Funding, Financials, Valuation & Investors
Bioniz is a biotechnology company focuses on discovering small peptides and molecules for the treatment of autoimmune diseases and cancer. ... How much funding has this organization …See details»
Bioniz Therapeutics Company Profile - Office Locations ... - Craft
Bioniz Therapeutics is a biopharmaceutical company. It is engaged in the discovery and development of peptide therapeutics that selectively and simultaneously inhibit multiple …See details»
Bioniz Therapeutics - Contacts, Employees, Board Members
Bioniz is a biotechnology company focuses on discovering small peptides and molecules for the treatment of autoimmune diseases and cancer. Search Crunchbase. Start Free Trial . Chrome …See details»
From Iran To CEO Of A Biotech Startup, Bioniz, With No Revenue …
Dec 20, 2017 Bioniz generates no revenue and Azimi says she’ll need at least $300 million in additional funding before she can produce a drug for sale. The company's current valuation: …See details»
Single-asset Equillium buys Bioniz for up to $329M ... - Fierce …
Feb 16, 2022 Equillium will buy Bioniz for about $21.4 million in stock and up to $57.5 million in development biobucks. The deal is further backloaded by up to $250 million in commercial …See details»
Almirall enters into an option agreement to acquire Bioniz …
Jan 9, 2020 Bioniz' lead product candidate, BNZ-01, has completed Phase 1 SAD and MAD clinical trials in healthy volunteers and is currently in Phase 1/2a clinical development in CTCL. …See details»
Single-asset Equillium buys Bioniz for up to $329M, adding 3 …
Feb 28, 2022 Bioniz has open applications with the FDA to run those studies, the company said. The acquisition also gives Equillium access to BNZ-2, an inhibitor of IL-15 and IL-21, that is …See details»
Equillium acquires Bioniz Therapeutics - 2022-02-16 - Crunchbase
Feb 16, 2022 Bioniz Therapeutics Bioniz is a biotechnology company focuses on discovering small peptides and molecules for the treatment of autoimmune diseases and cancer. Acquiring …See details»
Bioniz - VentureRadar
" Bioniz Therapeutics is a private biopharmaceutical company leading the discovery and development of first-in-class anti-cytokine therapies to treat cancer and autoimmune diseases …See details»
Equillium triples clinical pipeline with $329m Bioniz takeover
Feb 16, 2022 Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to three drug candidates via a $329 million agreement to acquire …See details»
Bioniz Therapeutics enters into an option agreement for …
Jan 9, 2020 Bioniz's lead product candidate, BNZ-1, has completed Phase 1 SAD and MAD clinical trials in healthy volunteers and is currently in Phase1/2a clinical development in CTCL. …See details»
Bioniz Therapeutics Receives Orphan Drug Designation from the …
Apr 6, 2021 Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and …See details»
BIONIZ: Announces Positive End of Phase 2 Meeting ... - FDA …
Jan 8, 2021 Bioniz Therapeutics, Inc., ("Bioniz"), a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of …See details»
Equillium Acquires Bioniz Therapeutics Significantly Expanding …
Feb 16, 2022 Equillium is also obligated to pay Bioniz stockholders up to $57.5 million in potential development milestone payments across three Bioniz clinical candidates (BNZ-1, …See details»
Phase 3 Trial of BNZ-1 To Be Initiated for Treatment of Relapsed ...
Jan 27, 2021 Based on positive feedback provided by the FDA, Bioniz Therapeutics announced it intends to launch a phase 3 clinical trial of the multi-cytokine inhibitor, BNZ-1, for the …See details»